Morin

Morin is an orally active plant-derived flavonoid. Morin inhibits ROS generation. Morin induces Apoptosis. Morin inhibits PTP1B (IC₅₀ of 15 μM) and activates the insulin receptor. Morin has a detoxifying effect. Morin can be used in diabetes, leukemia, colon cancer, cervical cancer, Parkinson's disease and hypertension research^{[1][2][3][4][5][6][7][8][9][10][11][12]}. In Vitro:Morin (25 μM, 1 h) protects V79-4 cells from hydrogen peroxide-induced damage by inhibiting ROS generation and by inducing catalase activation^[3].
Morin (100-500 μM, 6-48 h) inhibits the growth of human leukemia HL-60 cells via cell cycle arrest and induction of apoptosis through mitochondria dependent pathway^[4].
Morin (50 μM, 0-70 h) inhibits growth and activates the insulin metabolic pathway in HepG2 cells^[5].
Morin (100-500 μM, 48 h) shows anti-cancerous activity against HeLa cells at an IC₅₀ of 214.28 μM and causes morphological changes^[6].
Morin (5-50 μM, 24 h) exerts neuroprotective actions in PC12 cells, with attenuating loss of cell viability^[7].
In Vivo:Morin (5-100 mg/kg, i.p., daily, 5 days) exerts neuroprotective actions in Parkinson disease mice^[7].
Morin (10-150 mg/kg, i.p., 30 min prior to γ-irradiation) shows anticlastogenic activity against whole body gamma irradiation in Swiss albino mice^[8].
Morin (100 mg/kg, intragastrically, 10 days) exacerbates Cyclophosphamide (HY-17420)-induced suppression of body weight gain in rats^[9].
Morin (Morin hydrate form, 100 mg/kg, p.o., 10 days) attenuates Doxorubicin (HY-15142A)-induced heart and brain damage by reducing oxidative stress, inflammation and apoptosis in rats^[10].
Morin (50 mg/kg, p.o., everyday for a total period of 30 weeks) could exert a significant chemopreventive effect on colon carcinogenesis induced by DMH in rats^[11].
Morin (25-75 mg/kg, p.o., 6 weeks) exhibits strong antihypertensive effect against DOCA-salt induced hypertension in rats^[12].